FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging
Manuscript Number:
16-0326R1
Author(s):
Teresa J.H. Christianson, Yonas E. Geda, Clifford R. Jack Jr., David S. Knopman, Janina Krell-Roesch, Val J. Lowe, Mary M. Machulda, Michelle M. Mielke, Ronald C. Petersen, Anna Pink, Rosebud Roberts, Hanna Ruider, Gorazd B. Stokin
Disclosures
Teresa J.H. Christianson
Nothing to Disclose
Yonas E. Geda
Nothing to Disclose
Clifford R. Jack Jr.
Consulting Fees:
Eli Lily Co
Grants
Agency:
NIH
Agency:
Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation.
David S. Knopman
Consulting Fees:
DSMB for Lundbeck AD clinical trial; DSMB for DIAN study
Grants
Agency:
Lilly - for site participation in A4 study
Dates:
ongoing
Agency:
TAURX - for site participation in FTD clinical trial
Dates:
ongoing
Agency:
Biogen - for site participation in AD clinical trial
Dates:
ongoing
Janina Krell-Roesch
Nothing to Disclose
Val J. Lowe
Grants
Agency:
AVID Radiopharmaceuticals
Dates:
August, 2007 to present
Agency:
GE Healthcare
Dates:
March 2009 to present
Mary M. Machulda
Nothing to Disclose
Michelle M. Mielke
Consulting Fees:
I have consulted for Lysosomal Therapuetics, Inc and am on the scientific review board of the Alzheimer's Drug Discovery Foundation.
Ronald C. Petersen
Consulting Fees:
Pfizer, Inc., and Janssen Alzheimer Immunotherapy: Chair, Data Monitoring Committee
Hoffman-La Roche, Inc.: Consultant
Merck, Inc.: Consultant
Genentech, Inc.: Consultant
Biogen, Inc.: Consultant
Eli Lilly & Co.: Consultant